Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 2,844 shares of common stock at an average price of $57.1488 per share. The footnote explains these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
The filing states these “sell to cover” transactions are mandated by the issuer’s plan election and are not discretionary trades by the executive. After this tax-related sale, Finn directly holds 278,964 shares of Twist Bioscience common stock.
Twist Bioscience Corp’s Chief Accounting Officer Robert F. Werner reported a small, mandated share sale tied to equity compensation taxes. On May 4, 2026, he sold 164 shares of common stock at $57.1488 per share to cover tax withholding from vesting Restricted Stock Units.
The company’s equity incentive plan requires these “sell-to-cover” transactions, and the footnote states they are not discretionary trades by Werner. After this tax-related sale, he directly owns 54,635 shares of Twist Bioscience common stock.
Twist Bioscience reported strong top-line growth but remains unprofitable for the quarter ended March 31, 2026. Revenue rose 19% to $110.7 million, with DNA synthesis and protein solutions up 28% and NGS applications up 12%, lifting gross margin to 51.6% from 49.6%.
The company posted a quarterly net loss of $44.0 million and a six‑month loss of $74.5 million, driven partly by higher selling, general and administrative expenses and $7.2 million of litigation settlement costs, net of recoveries. Operating cash outflow was $42.4 million for the first half.
Twist ended the quarter with $171.7 million in cash, cash equivalents and short‑term investments and expects this to fund operations for at least one year. It also entered a $20.0 million co‑exclusive license for Invenra’s B‑Body bispecific antibody platform and a related $13.8 million equity investment to deepen its therapeutics discovery offerings.
Twist Bioscience reported strong top-line growth but remains unprofitable for the quarter ended March 31, 2026. Revenue rose 19% to $110.7 million, with DNA synthesis and protein solutions up 28% and NGS applications up 12%, lifting gross margin to 51.6% from 49.6%.
The company posted a quarterly net loss of $44.0 million and a six‑month loss of $74.5 million, driven partly by higher selling, general and administrative expenses and $7.2 million of litigation settlement costs, net of recoveries. Operating cash outflow was $42.4 million for the first half.
Twist ended the quarter with $171.7 million in cash, cash equivalents and short‑term investments and expects this to fund operations for at least one year. It also entered a $20.0 million co‑exclusive license for Invenra’s B‑Body bispecific antibody platform and a related $13.8 million equity investment to deepen its therapeutics discovery offerings.
TWST submitted a Rule 144 notice listing proposed and recent sales of common stock by Emily M. Leproust. The filing lists multiple sale dates and share counts tied to restricted stock vesting and open-market sales, with individual transactions on 02/23/2026, 03/06/2026, 03/20/2026, 04/21/2026, 04/22/2026, and a vesting entry on 05/01/2026.
The filing itemizes share quantities and dollar amounts for each date, indicating routine insider dispositions and a vesting event reported under Rule 144.
TWST submitted a Rule 144 notice listing proposed and recent sales of common stock by Emily M. Leproust. The filing lists multiple sale dates and share counts tied to restricted stock vesting and open-market sales, with individual transactions on 02/23/2026, 03/06/2026, 03/20/2026, 04/21/2026, 04/22/2026, and a vesting entry on 05/01/2026.
The filing itemizes share quantities and dollar amounts for each date, indicating routine insider dispositions and a vesting event reported under Rule 144.
TWST affiliate submitted a Form 144 notice to sell Common stock. The notice lists 1,116 shares of Common stock tied to restricted stock vesting dated 05/01/2026 and a broker designation at Fidelity Brokerage Services. The filing also reports four completed dispositions in the past three months totaling 41, (…) recent transactions by Paula Green on 02/17/2026, 02/23/2026, 03/06/2026, and 03/20/2026 with per‑trade proceeds shown in the excerpt.
TWST affiliate submitted a Form 144 notice to sell Common stock. The notice lists 1,116 shares of Common stock tied to restricted stock vesting dated 05/01/2026 and a broker designation at Fidelity Brokerage Services. The filing also reports four completed dispositions in the past three months totaling 41, (…) recent transactions by Paula Green on 02/17/2026, 02/23/2026, 03/06/2026, and 03/20/2026 with per‑trade proceeds shown in the excerpt.
Reporting person filed a Form 144 reporting a proposed sale of 2,844 shares of Common Stock tied to restricted stock vesting on 05/01/2026. The notice lists the 2,844 shares with an aggregate value of $162,531.19 and a filing date of 05/04/2026. The excerpt also discloses multiple sales during the past 3 months by Patrick Finn: 02/12/2026 (3,500 shares), 02/13/2026 (1,750 shares), 02/17/2026 (68,967 shares), 02/23/2026 (4,294 shares), and 04/23/2026 (2,321 shares), with the per‑trade dollar amounts shown in the table.
Reporting person filed a Form 144 reporting a proposed sale of 2,844 shares of Common Stock tied to restricted stock vesting on 05/01/2026. The notice lists the 2,844 shares with an aggregate value of $162,531.19 and a filing date of 05/04/2026. The excerpt also discloses multiple sales during the past 3 months by Patrick Finn: 02/12/2026 (3,500 shares), 02/13/2026 (1,750 shares), 02/17/2026 (68,967 shares), 02/23/2026 (4,294 shares), and 04/23/2026 (2,321 shares), with the per‑trade dollar amounts shown in the table.
Insider filing (Form 144): The filing reports multiple small sales of Common Stock by Robert F. Werner under Rule 144. The disclosed transactions show sales of 7,000 shares on 02/04/2026, 1,693 shares on 02/23/2026, and 246 shares on 03/06/2026. The securities included restricted stock that vested on 05/01/2026 and were listed as compensation-related on the securities to be sold line.
Insider filing (Form 144): The filing reports multiple small sales of Common Stock by Robert F. Werner under Rule 144. The disclosed transactions show sales of 7,000 shares on 02/04/2026, 1,693 shares on 02/23/2026, and 246 shares on 03/06/2026. The securities included restricted stock that vested on 05/01/2026 and were listed as compensation-related on the securities to be sold line.
TWST submitted a Form 144 reporting a planned sale of common stock tied to restricted stock vesting with an effective date of 05/01/2026. The filing lists multiple recent dispositions by Dennis H. Cho in February–March 2026, each showing share counts and gross proceeds.
TWST submitted a Form 144 reporting a planned sale of common stock tied to restricted stock vesting with an effective date of 05/01/2026. The filing lists multiple recent dispositions by Dennis H. Cho in February–March 2026, each showing share counts and gross proceeds.
Twist Bioscience reported strong fiscal second quarter 2026 results, highlighted by record revenue of $110.7 million, up 19% from $92.8 million a year earlier and marking the 13th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose 28% to $53.3 million, while NGS Applications revenue increased 12% to $57.4 million, with both segments growing sequentially.
Gross margin improved to 51.6% from 49.6%, reflecting better profitability on each dollar of sales. Operating expenses were mixed: research and development fell to $19.7 million, but selling, general and administrative costs climbed to $76.1 million. The company also recorded $7.2 million in litigation settlement costs tied to a securities class action.
As a result, net loss widened slightly to $44.0 million, or $0.71 per share, compared with $39.3 million, or $0.66 per share, in the prior-year quarter. Adjusted EBITDA improved modestly to a loss of $13.3 million from $14.8 million. Twist ended March 31, 2026 with $172 million in cash, cash equivalents and short‑term investments and shipped products to approximately 2,583 customers.
Management raised full‑year 2026 revenue guidance to a range of $442 million to $447 million, implying 17–19% growth, and continues to target adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while keeping gross margin above 52% for the year.
Twist Bioscience reported strong fiscal second quarter 2026 results, highlighted by record revenue of $110.7 million, up 19% from $92.8 million a year earlier and marking the 13th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose 28% to $53.3 million, while NGS Applications revenue increased 12% to $57.4 million, with both segments growing sequentially.
Gross margin improved to 51.6% from 49.6%, reflecting better profitability on each dollar of sales. Operating expenses were mixed: research and development fell to $19.7 million, but selling, general and administrative costs climbed to $76.1 million. The company also recorded $7.2 million in litigation settlement costs tied to a securities class action.
As a result, net loss widened slightly to $44.0 million, or $0.71 per share, compared with $39.3 million, or $0.66 per share, in the prior-year quarter. Adjusted EBITDA improved modestly to a loss of $13.3 million from $14.8 million. Twist ended March 31, 2026 with $172 million in cash, cash equivalents and short‑term investments and shipped products to approximately 2,583 customers.
Management raised full‑year 2026 revenue guidance to a range of $442 million to $447 million, implying 17–19% growth, and continues to target adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while keeping gross margin above 52% for the year.
Vanguard Capital Management reported beneficial ownership of 3,101,909 shares of Twist Bioscience Corp common stock, representing 5.05% of the class.
The filing (Schedule 13G) shows sole dispositive power over 3,101,909 shares and sole voting power for 462,865 shares. The report lists the issuer CUSIP 90184D100 and is signed by Ashley Grim on 04/30/2026.